60382 Federal Register / Vol. 72, No. 205 / Wednesday, October 24, 2007 / Notices 

Use of HDAC Inhibitors for the 

Prevention and Cure for Brain 

Metastases of Cancers 

Description of Technology: The 

increased survival of primary and 

metastatic cancers consequential of 

improved therapies has resulted in 

increased brain metastases. Few 

treatment options are available for 

cancer patients with central nervous 

system (CNS) metastasis. There is a 

need for new treatment options for CNS 

metastases especially brain metastases 

originating outside the CNS. 

The present invention provides a 

method of treating a localized 

carcinoma CNS metastasis of extra-CNS 

origin. More specifically, the method 

comprises of treating a localized 

carcinoma CNS metastasis of extra-CNS 

origin with a histone deacetylase 

(HDAC) inhibitor (HDACI) originating in 

one or more organs such as lung, breast, 

liver, colon, and prostate. The HDACI 

can be any HDACI that is capable of 

crossing the blood-brain barrier (BBB) 

such as vorinostat. 

Advantages: Vorinostat has been 

approved by the FDA for the treatment 

of cutaneous manifestations in patients 

with cutaneous T-cell lymphoma 

(CTCL) who have progressive, persistent 

or recurrent disease on or following two 

systemic therapies, and as such, has 

efficacy and tolerability data. 

Benefits: More than 40,000 breast 

cancer deaths are estimated to occur in 

2007. Majority of these deaths are due 

to metastases of the breast cancer. 

Approximately, 10%–20% of women 

with metastatic breast cancer are 

estimated to develop brain metastasis 

and the median survival after brain 

cancer metastasis is only one year. This 

technology may effectively treat breast 

cancer brain metastases and thus 

improve overall survival and quality of 

life of patients suffering from cancer. 

The current cancer chemotherapeutic 

market is valued at $42 billion and 

expected to grow. 

Inventors: Patricia S. Steeg et al. 

(NCI). 

Development Status: In vivo animal 

model data available with vorinostat. 

Patent Status: U.S. Provisional 

Application No. 60/891,856 filed 02 Feb 

2007 (HHS Reference No. E–084–2007/ 

0–US–01). 

Licensing Contact: John Stansberry; 

301/435–5236; stansbej@mail.nih.gov. 

Dated: October 11, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–20909 Filed 10–23–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice of Meeting: Secretary’s 

Advisory Committee on Genetics, 

Health, and Society 

Pursuant to Public Law 92–463, 

notice is hereby given of the fourteenth 

meeting of the Secretary’s Advisory 

Committee on Genetics, Health, and 

Society (SACGHS), U.S. Public Health 

Service. The meeting will be held from 

8:30 a.m. to approximately 5:30 p.m. on 

Monday, November 19, 2007 and 8:30 

a.m. to approximately 5:30 p.m. on 

Tuesday, November 20, 2007, at the 

Ronald Reagan Building and 

International Trade Center—1300 

Pennsylvania Avenue, NW., 

Washington, DC 20004. The meeting 

will be open to the public with 

attendance limited to space available. 

The meeting also will be Web cast. 

The agenda will focus on three key 

issues—finalization of the SACGHS 

report on the opportunities and 

challenges in realizing the promise of 

pharmacogenomics; the oversight of 

genetic testing; and the preparedness of 

health professionals to incorporate 

genetic and genomic tests and services 

into clinical and public health practice. 

With regard to the oversight of genetic 

testing, SACGHS’ draft report to the 

Secretary of Health and Human Services 

will be released for public comment in 

early November. The Committee will 

provide an extended period of time 

during the November meeting for 

members of the public to provide their 

perspectives on the oversight issues and 

comments on the Committee’s draft 

report and recommendations. The 

Committee will also be briefed about an 

international analysis of oversight 

systems for genetic testing with a focus 

on the U.S. system. 

As always, the Committee welcomes 

hearing from anyone wishing to provide 

public comment on any issue related to 

genetics, health and society. Individuals 

who would like to provide public 

comment should notify the SACGHS 

Executive Secretary. Ms. Sarah Carr, by 

telephone at 301–496–9838 or e-mail at 

carr@od.nih.gov. The SACGHS office is 

located at 6705 Rockledge Drive, Suite 

750, Bethesda, MD 20892. Anyone 

planning to attend the meeting who is 

in need of special assistance, such as 

sign language interpretation or other 

reasonable accommodations, is also 

asked to contact the Executive 

Secretary. 

Under authority of 42 U.S.C. 217a, 

Section 222 of the Public Health Service 

Act, as amended, the Department of 

Health and Human Services established 

SACGHS to serve as a public forum for 

deliberations on the broad range of 

human health and societal issues raised 

by the development and use of genetic 

and genomic technologies and, as 

warranted, to provide advice on these 

issues. The draft meeting agenda and 

other information about SACGHS, 

including information about access to 

the Web cast, will be available at the 

following Web site: http:// 

www4.od.nih.gov/oba/sacghs.htm. 

Dated: October 17, 2007. 

Jennifer Spaeth, 

Director, NIH Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–5240 Filed 10–23–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Small 

Grants for Behavioral Research in Cancer 

Control [R03]. 

Date: November 14, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Rockville Executive Meeting 

Center, 1750 Rockville Pike, Rockville, MD 

20852. 

Contact Person: Rhonda J. Moore, PhD., 

Scientific Review Administrator, Special 

Review and Logistics Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 6116 Executive Boulevard, 

Suite 701, Room 7151, Bethesda, MD 20892–

8329, 301–451–9385, moorerh@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Community Clinical Oncology Program & 

Minority Based Community Clinical 

Oncology. 


yshivers on PROD1PC62 with NOTICES
Federal Register / Vol. 72, No. 205 / Wednesday, October 24, 2007 / Notices 60383 

Date: November 26–27, 2007. 

Time: 7 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Courtyard Marriott Gaithersburg 

Washingtonian Ctr., 204 Boardwalk Place, 

Gaithersburg, MD 20878. 

Contact Person: Gerald G. Lovinger, PhD., 

Scientific Review Administrator, Special 

Review and Logistics Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 8101, 

Bethesda, MD 20892–8329, 301–496–7987, 

lovingeg@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS). 

Dated: October 16, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–5236 Filed 10–23–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the meeting of the 

President’s Cancer Panel. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The meeting 

will be closed to the public in 

accordance with the provisions set forth 

in section 552b(c)(9)(B), Title 5 U.S.C., 

as amended, because the premature 

disclosure of information and the 

discussions would be likely to 

significantly frustrate implementation of 

recommendations. 

Name of Committee: President’s Cancer 

Panel. 

Date: December 3, 2007. 

Open: December 3, 2007, 7:30 a.m.–3:30 

p.m. 

Agenda: Strategies for Maximizing the 

Nation’s Investment in Cancer. 

Place: Ritz Carlton San Juan Hotel, 6961 

Avenue of the Governors, Isla Verde, 

Carolina, Puerto Rico 00979. 

Closed: December 3, 2007, 4 p.m.–6 p.m. 

Agenda: Strategies for Maximizing the 

Nation’s Investment in Cancer and discuss 

potential topics for the 2008/2009 series. 

Place: Ritz Carlton San Juan Hotel, 6961 

Avenue of the Governors, Isla Verde, 

Carolina, Puerto Rico 00979. 

Contact Person: Abby Sandler, Ph.D., 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 

Building 6116, Room 212, 6116 Executive 

Boulevard, Bethesda, MD 20892, 301/451–

9399. 

Any interested person may file written 

comments with the committee by forwarding 

the comments to the Contact Person listed on 

this notice. The comments should include 

the name, address, telephone number and, 

when applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

deainfo.nci.nih.gov/advisory/pcp/pcp.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS). 

Dated: October 16, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–5237 Filed 10–23–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the meeting of the 

National Cancer Advisory Board. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

A portion of the meeting will be 

closed to the public in accordance with 

the provisions set forth in section 

552b(6), as amended. The discussions 

could disclose personal information 

concerning NCI Staff and/or its 

contractors, the disclosure of which 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Advisory Board. 

Open: November 27, 2007, 8 a.m. to 4:45 

p.m. 

Agenda: Program reports and 

presentations, Business of the Board. 

Place: National Cancer Institute, 9000 

Rockville Pike, Building 31, C Wing, 6th 

Floor, Conference Room 10, Bethesda, 

Maryland 20892. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, Maryland 20892–8327, (301) 496–

5147. 

Name of Committee: National Cancer 

Advisory Board. 

Closed: November 27, 2007, 4:45 p.m. to 

5:30 p.m. 

Agenda: Review intramural program site 

visit outcomes; Discussion of confidential 

personnel issues. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, Maryland 20892–8327, (301) 496–

5147. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/ncab.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398 Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS). 

Dated: October 17, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–5242 Filed 10–23–07; 8:45 am] 

BILLING CODE 4140–01–M 


yshivers on PROD1PC62 with NOTICES